Upstream Bio (NASDAQ:UPB) Shares Down 3.4% – Time to Sell?

by · The Cerbat Gem

Upstream Bio, Inc. (NASDAQ:UPB – Get Free Report) dropped 3.4% during trading on Tuesday . The stock traded as low as $27.52 and last traded at $27.8470. Approximately 51,538 shares changed hands during trading, a decline of 87% from the average daily volume of 400,492 shares. The stock had previously closed at $28.83.

Wall Street Analysts Forecast Growth

Several research firms recently commented on UPB. Evercore ISI assumed coverage on shares of Upstream Bio in a report on Tuesday, November 18th. They issued an “outperform” rating and a $40.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Upstream Bio in a report on Wednesday, October 8th. Mizuho raised Upstream Bio to a “strong-buy” rating in a report on Thursday, December 18th. Truist Financial started coverage on Upstream Bio in a report on Tuesday, October 14th. They set a “buy” rating and a $47.00 target price for the company. Finally, Lifesci Capital started coverage on shares of Upstream Bio in a report on Tuesday, December 2nd. They issued an “outperform” rating and a $43.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Upstream Bio currently has an average rating of “Moderate Buy” and an average price target of $45.25.

View Our Latest Stock Report on UPB

Upstream Bio Stock Performance

The stock’s 50 day moving average price is $26.37 and its 200-day moving average price is $19.38. The company has a market cap of $1.48 billion, a PE ratio of -14.59 and a beta of 1.83.

Upstream Bio (NASDAQ:UPB – Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.15. Upstream Bio had a negative return on equity of 28.71% and a negative net margin of 4,366.77%.The firm had revenue of $0.68 million for the quarter, compared to the consensus estimate of $0.65 million. On average, analysts anticipate that Upstream Bio, Inc. will post -4.3 EPS for the current year.

Institutional Investors Weigh In On Upstream Bio

Institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. raised its stake in shares of Upstream Bio by 1,963.9% during the third quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company’s stock valued at $57,000 after acquiring an additional 2,887 shares during the last quarter. BNP Paribas Financial Markets raised its position in Upstream Bio by 229.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock valued at $34,000 after purchasing an additional 2,158 shares during the last quarter. Legal & General Group Plc lifted its holdings in Upstream Bio by 83.0% in the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after buying an additional 1,440 shares during the period. CWM LLC grew its position in shares of Upstream Bio by 107.5% in the 2nd quarter. CWM LLC now owns 3,312 shares of the company’s stock worth $36,000 after buying an additional 1,716 shares during the last quarter. Finally, Ameritas Investment Partners Inc. increased its stake in shares of Upstream Bio by 95.3% during the second quarter. Ameritas Investment Partners Inc. now owns 3,558 shares of the company’s stock valued at $39,000 after buying an additional 1,736 shares during the period.

About Upstream Bio

(Get Free Report)

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.

See Also